Cadrenal Therapeutics, a biopharmaceutical company developing tecarfarin, a novel oral anticoagulant, has initiated discussions with Abbott about a potential pivotal study that would evaluate the efficacy and safety of tecarfarin in preventing blood clots in patients with recently implanted left ventricular assist devices (LVADs).   Tecarfarin, a late-stage Vitamin K Antagonist (VKA), is designed to offer a safer and more predictable anticoagulation profile compared to existing options. The dr...